Hormonal treatment of breast cancer: optimal sequence and issues of overcoming the resistance


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Endocrine therapy is important component in the treatment of receptor-positive metastatic breast cancer (RPBC), and allows achieving good results with low toxicity of treatment. When hormonal therapy should be administered, it is necessary to consider the level of Ki-67 and HER2-status in addition to clinical data. The most effective first-line drugs include aromatase inhibitors (non-steroidal and steroidal), fulvestrant, tamoxifen. If first-line treatment is effective, transition to the second and subsequent lines of hormone therapy is appropriate. A number of studies have shown high treatment effect with adding targeted agents: trastuzumab or lapatinib + aromatase inhibitor for HER2 overexpression in the first line; gefitinib +anastrozole in first-line hormonal therapy of advanced RPBC, everolimus + exemestane or tamoxifen in the second-line hormonal therapy.

Texto integral

Acesso é fechado

Bibliografia

  1. Anderson W.F., Chatterjee N., Ershler W.B., et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76:27-36.
  2. Barrios C.H., Sampaio C., Vinholes J., Caponero R. What is the role of chemotherapy in estrogen receptorpositive, advanced breast cancer? Annals Oncol 2009;20:1157-62.
  3. Goldhirsch A., Wood W.C., Coates A.S., et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals Oncol 2011;22:1736-47.
  4. Viale G., Giobbie-Hurder A., Regan M.M., et al. Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569-75.
  5. Kuter I., Hegg R., Singer C.F., et al. Fulvestrant 500 mg vs 250 mg: First results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2007;106(abstr. 589):7.
  6. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 1986;4:186-93.
  7. Wilcken N., Hornbuckle J., Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003;CD002747.
  8. Buzdar A.U., Jones S.E., Vogel C.L., et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997;79:730-39.
  9. Jonat W., Howell A., Blomqvist C., et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
  10. Buzdar A.U., Jonat W., Howell A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group Cancer 1998;83:1142-52.
  11. Buzdar A., Douma J., Davidson N., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-66.
  12. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-61.
  13. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-411.
  14. Nabholtz J.M., Bonneterre J., Buzdar A., et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684-89.
  15. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-109.
  16. Paridaens R.J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90.
  17. Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38.
  18. Di Leo A., Jerusalem G., Petruzelka L., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600.
  19. Robertson J.F., Llombart-Cussac A., Rolski J., et al. Activity of fulvestrant 500 mg versus anastrozole
  20. mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-35.
  21. Robertson J.F.R., Lindemann J.P.O., Llombart-Cussac A., et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the 'FIRST'study. Cancer Res 2010;70(24):76.
  22. Bergh J., Jonsson P.E., Lidbrink E.K., et al. FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer. JCO 2012;30(16):1919-25.
  23. Robertson J.F., Howell A., Gorbunova V.A., et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005;92(2):169-74.
  24. Vergote I., Robertson J.F., Kleeberg U., et al. Postmenopausal women who progress on fulvestrant ("Faslodex”) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79207-11.
  25. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-109.
  26. Thurlimann B., Hess D., Koberle D., et al. Anastrozole ("Arimidex") versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the doubleblind cross-over SAKK trial 21/95 - a substudy of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004;85: 247-54.
  27. Pietras J.R. Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer. The Oncologist 2006; 11:704-17.
  28. Arpino G., Green S.J., Allred D.C., et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670-76.
  29. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-16.
  30. Robertson J.F.R., Steger G.G., Neven P. Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol 2010; 21(6):1246-53.
  31. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37.
  32. Johnston S., Pegram M., Press M., et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HRC) metastatic breast cancer (MBC): first results from the EGF30008 Trial. San Antonio Breast Cancer Symposium 2008;abstr.46.
  33. Smith I.E., Walsh G., Skene A., et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. Jl of Clinical Oncology 2007; 25:3816-22.
  34. Mita M., de Bono J., Patnaik A., et al. A phase II and biologic correlative study investigating anastrozole in combination with gefitinib in post menopausal patients with estrogen receptor positive metastatic breast carcinoma who have previously failed hormonal therapy. Breast Cancer Research and Treatment 2005;94:abstr. 1117.
  35. Cristofanilli M., Valero V., Mangalik A., et al. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HRC) metastatic breast cancer (MBC). J Clin Oncol 2008;26:abstr.1012.
  36. Osborne K., Neven P., Dirix L., et al. Randomized phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2007;abstr.2067.
  37. Baselga J., Semiglazov V., van Dam P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-37.
  38. Hortobagyi G.N., Piccart M., Rugo H., et al. Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. Abstracts from the 34th Annual SABCS 2011;abstr.3-7.
  39. Bachelot T., Bourgier C., Cropet C., et al. TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors. SABCS 2010;abstr. 1 -6.
  40. Johnston S.R., Semiglazov V.F., Manikhas G.M., et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Research and Treatment 2008; 110:327-35.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2012

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies